Cencora, Inc. (NYSE: COR)

Cencora, Inc. (COR), a Delaware corporation, is a prominent player in the pharmaceutical industry, which is projected to grow at a compound annual growth rate of approximately 7.9% from 2022 to 2027. This growth is driven by factors such as an aging population, the introduction of new pharmaceuticals, increased use of generic and biosimilar pharmaceuticals, and the increased use of drug therapies.

Cencora's primary business activities involve the distribution of a wide range of pharmaceutical products and services. The company offers brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services. These offerings are distributed to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.

The company's revenue generation is primarily based on the distribution of pharmaceuticals. Its main products include plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products. Cencora's competitive advantages lie in its large customer base, diversified product offerings, and strong relationships with pharmaceutical manufacturers and healthcare providers. Key competitors include McKesson Corporation, Cardinal Health, Inc., and UPS Logistics.

Cencora's customers include institutional and retail healthcare providers, as well as pharmaceutical manufacturers. The company's top 10 customers, including governmental agencies and group purchasing organizations, represented approximately 66% of revenue in the fiscal year ended September 30, 2023.

Cencora's workforce is a critical component of its success. The company has a diverse and inclusive workforce of approximately 46,000 employees, with approximately 42,000 being full-time employees. The company encourages and supports employee growth and advancement through various benefits and programs, including leadership and professional development programs, tuition reimbursement, and opportunities to volunteer and participate in mentorship and support programs.

In addition to its business operations, Cencora is committed to creating a positive work environment where everyone can thrive and find opportunities to grow, learn, and pursue their passions while contributing to the company's purpose to create healthier futures. The company has implemented various initiatives to support its employees' health and wellbeing, including a comprehensive benefit and compensation package, employee assistance programs, and a myWellbeing program that focuses on the physical, emotional, financial, and social aspects of wellness.

Cencora is subject to extensive oversight by United States, United Kingdom, and European Union governmental entities and is subject to, and affected by, a variety of laws, regulations, and policies. The company is regulated by the U.S. Drug Enforcement Administration, the U.S. Food and Drug Administration, the U.S. Department of Justice, and various other federal and state authorities, and is subject to fraud and abuse laws, including the federal anti-kickback statute and False Claims Act.

The company is also subject to various federal, state, and local environmental laws, including with respect to the sale, transportation, storage, handling, and disposal of hazardous or potentially hazardous substances, as well as laws relating to safe working conditions and laboratory practices. Additionally, Cencora is subject to data privacy and security regulations, including the Health Insurance Portability and Accountability Act of 1996, the General Data Protection Regulation, the Personal Information Protection and Electronic Documents Act of 2000, and U.S. state and Canadian provincial privacy, consumer protection, and breach notification laws.